Shockwave Medical

Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company operates 2 divisions: Innovative Medicine (64% of 2025 revenues) and MedTech (36% of 2025 revenues). Major products produced by the Innovative Medicine division are CARVYKTI (ciltacabtagene autoleucel) for multiple myeloma (2.0% of revenues); DARZALEX (daratumumab and hyaluronidase-fihj), also for multiple myeloma (15.2% of revenues); ERLEADA (apalutamide), for prostate cancer (3.8% of revenues); REMICADE (infliximab), for inflammatory diseases (1.9% of revenues); SIMPONI/SIMPONI ARIA (golimumab), for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis (pJIA) (2.8% of revenues); STELARA (ustekinumab), for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis (6.5% of revenues); TREMFYA (guselkumab), for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis (5.5% of revenues); INVEGA SUSTENNA/XEPLION (paliperidone palmitate), for schizophrenia (4.1% of revenues); SPRAVATO (Esketamine), a nasal spray for depression (1.8% of revenues); OPSUMIT (macitentan)/OPSYNVI (macitentan/tadalafil) for pulmonary arterial hypertension (2.5% of revenues); and UPTRAVI (selexipag) for pulmonary arterial hypertension (2.0% of revenues). The MedTech division produces products used for cardiovascular (9.5% of revenues), orthopaedics (DePuy Synthes) (9.8% of revenues), surgery (Ethicon) (10.8% of revenues), and vision treatments (Johnson & Johnson Vision) (5.8% of revenues).